The negative impact on LFLY's stock price is directly tied to its poor financial results for Q1, which typically leads to a loss of investor confidence. Additionally, the DEA's questioning of marijuana's medical value could pose regulatory challenges and affect the company's future growth prospects in the cannabis industry. Both factors are critical for investors, influencing the stock's short-term performance.